Terms: = Germ cell tumor AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Clinical Outcome
50 results:
1. N7-methylguanosin regulators-mediated methylation modification patterns and characterization of the immune microenvironment in lower-grade glioma.
Maimaiti A; Feng Z; Liu Y; Turhon M; Xie Z; Baihetiyaer Y; Wang X; Kasimu M; Jiang L; Wang Y; Wang Z; Pei Y
Eur J Med Res; 2023 Mar; 28(1):144. PubMed ID: 36998056
[TBL] [Abstract] [Full Text] [Related]
2. β3-adrenergic receptor on tumor-infiltrating lymphocytes sustains IFN-γ-dependent pd-l1 expression and impairs anti-tumor immunity in neuroblastoma.
Bruno G; Nastasi N; Subbiani A; Boaretto A; Ciullini Mannurita S; Mattei G; Nardini P; Della Bella C; Magi A; Pini A; De Marco E; Tondo A; Favre C; Calvani M
Cancer Gene Ther; 2023 Jun; 30(6):890-904. PubMed ID: 36854895
[TBL] [Abstract] [Full Text] [Related]
3. TIMEAS, a promising method for the stratification of testicular germ cell tumor patients with distinct immune microenvironment, clinical outcome and sensitivity to frontline therapies.
Meng J; Gao J; Li X; Gao R; Lu X; Zhou J; Yan F; Wang H; Liu Y; Hao Z; Zhang X; Liang C
Cell Oncol (Dordr); 2023 Jun; 46(3):745-759. PubMed ID: 36823338
[TBL] [Abstract] [Full Text] [Related]
4. Characterization and dynamics of the soluble immunological microenvironment in melanoma patients undergoing radiotherapy.
Oertel M; Borrmann K; Baehr A; Eich HT; Greve B
Radiat Oncol; 2022 Nov; 17(1):194. PubMed ID: 36443849
[TBL] [Abstract] [Full Text] [Related]
5. HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling.
Arkhypov I; Özbay Kurt FG; Bitsch R; Novak D; Petrova V; Lasser S; Hielscher T; Groth C; Lepper A; Hu X; Li W; Utikal J; Altevogt P; Umansky V
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113897
[TBL] [Abstract] [Full Text] [Related]
6. Appraisal of clinicopathological prognosticators in advanced acral lentiginous melanoma with characterization of pd-l1 and CD8/CD4 immunoprofiles.
Chuang IC; Jang CS
Jpn J Clin Oncol; 2022 Sep; 52(9):975-981. PubMed ID: 35662346
[TBL] [Abstract] [Full Text] [Related]
7. pd-l1 expression in 117 sinonasal mucosal melanomas and its association with clinical outcome.
Wang L; Liu H
Ann Diagn Pathol; 2022 Oct; 60():151976. PubMed ID: 35660809
[TBL] [Abstract] [Full Text] [Related]
8. Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients.
Del Bianco P; Pinton L; Magri S; Canè S; Masetto E; Basso D; Padovan M; Volpin F; d'Avella D; Lombardi G; Zagonel V; Bronte V; Della Puppa A; Mandruzzato S
Front Immunol; 2021; 12():809826. PubMed ID: 35069595
[TBL] [Abstract] [Full Text] [Related]
9. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
Forde PM; Anagnostou V; Sun Z; Dahlberg SE; Kindler HL; Niknafs N; Purcell T; Santana-Davila R; Dudek AZ; Borghaei H; Lanis M; Belcaid Z; Smith KN; Balan A; White JR; Cherry C; Ashok Sivakumar IK; Shao XM; Chan HY; Singh D; Thapa S; Illei PB; Pardoll DM; Karchin R; Velculescu VE; Brahmer JR; Ramalingam SS
Nat Med; 2021 Nov; 27(11):1910-1920. PubMed ID: 34750557
[TBL] [Abstract] [Full Text] [Related]
10. T-cell Responses in Merkel cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
Gehrcken L; Sauerer T; Schaft N; Dörrie J
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
[TBL] [Abstract] [Full Text] [Related]
11. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.
Najjar YG; McCurry D; Lin H; Lin Y; Zang Y; Davar D; Karunamurthy A; Drabick JJ; Neves RI; Butterfield LH; Ernstoff MS; Puzanov I; Skitzki JJ; Bordeaux J; Summit IB; Bender JO; Kim JY; Chen B; Sarikonda G; Pahuja A; Tsau J; Alfonso Z; Laing C; Pingpank JF; Holtzman MP; Sander C; Rose A; Zarour HM; Kirkwood JM; Tarhini AA
Clin Cancer Res; 2021 Aug; 27(15):4195-4204. PubMed ID: 33753453
[TBL] [Abstract] [Full Text] [Related]
12. Immune Profile Analysis in Peripheral Blood and tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract] [Full Text] [Related]
13. Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients.
Huber V; Di Guardo L; Lalli L; Giardiello D; Cova A; Squarcina P; Frati P; Di Giacomo AM; Pilla L; Tazzari M; Camisaschi C; Arienti F; Castelli C; Rodolfo M; Beretta V; Di Nicola M; Maio M; Del Vecchio M; de Braud F; Mariani L; Rivoltini L
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589521
[TBL] [Abstract] [Full Text] [Related]
14. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
[TBL] [Abstract] [Full Text] [Related]
15. pd-l1 Expression in 65 Conjunctival Melanomas and Its Association with clinical outcome.
Lassalle S; Nahon-Esteve S; Frouin E; Boulagnon-Rombi C; Josselin N; Cassoux N; Barnhill R; Scheller B; Baillif S; Hofman P
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266349
[TBL] [Abstract] [Full Text] [Related]
16. Typical and Atypical Carcinoid tumors of the Mediastinum: A Biomarker Analysis of 27 Cases With clinical Correlation.
Zaleski M; Kalhor N; Moran CA
Int J Surg Pathol; 2021 Jun; 29(4):358-367. PubMed ID: 33243039
[TBL] [Abstract] [Full Text] [Related]
17. cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma.
Melaiu O; Chierici M; Lucarini V; Jurman G; Conti LA; De Vito R; Boldrini R; Cifaldi L; Castellano A; Furlanello C; Barnaba V; Locatelli F; Fruci D
Nat Commun; 2020 Nov; 11(1):5992. PubMed ID: 33239635
[TBL] [Abstract] [Full Text] [Related]
18. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract] [Full Text] [Related]
19. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
[TBL] [Abstract] [Full Text] [Related]
20. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract] [Full Text] [Related]
[Next]
